SABS
SAB Biotherapeutics Inc
3.10$
+4.0%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 11.0% | 70.2% | 65.8% | 64.0% | 60.5% | 53.8% | 42.8% | 30.9% | 61.7% | 58.5% | 45.4% | 45.3% | |
| 8.6% | 67.4% | 19.7% | 27.9% | 17.0% | 20.1% | 14.8% | 12.3% | 16.0% | 6.1% | 8.3% | 3.5% | |
| 8.6% | 67.4% | 61.7% | 60.3% | 56.5% | 47.0% | 33.7% | 19.0% | 60.4% | 55.9% | 43.2% | 43.1% | |
| 0.0% | 0.0% | 0.3% | 0.4% | 0.2% | 0.1% | 0.1% | – | 0.3% | 0.5% | 0.6% | 0.8% | |
| 46.2% | 31.7% | 26.0% | 25.5% | 31.4% | 41.2% | 43.8% | 60.1% | 10.0% | 12.3% | 8.5% | 9.8% | |
| 32.5% | 12.9% | 11.6% | 12.2% | 16.4% | 18.1% | 25.3% | 35.4% | 5.9% | 6.2% | 4.0% | 4.9% | |
| 4.2% | 2.2% | 2.1% | 2.0% | 1.0% | 1.8% | 2.8% | 3.2% | 0.5% | 0.6% | 0.4% | 0.3% | |
| 3.8% | 1.1% | 1.7% | 1.9% | 2.4% | 3.8% | 6.6% | 8.7% | 1.6% | 1.8% | 1.4% | 1.6% | |
| 53.8% | 68.3% | 74.0% | 74.5% | 68.6% | 58.8% | 56.2% | 39.9% | 90.0% | 87.7% | 91.5% | 90.2% | |
| -237.2% | -107.3% | -133.2% | -165.5% | -209.6% | -281.0% | -339.4% | -462.9% | -51.3% | -64.2% | -52.2% | -63.9% | |
| 18.5% | 7.1% | 12.9% | 15.0% | 17.2% | 21.0% | 24.4% | 30.8% | 42.4% | 27.6% | 21.6% | 33.5% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.